This map shows where obesity and diabetes are happening in the US, by county. It shows each component of the map as its own layer, and also shows the patterns overlapping. Diabetes prevalence (% of adults)Obesity prevalence (% of adults)This data can be used to assess the health factors, and answer questions such as:Are certain counties more/less at risk in regards to diabetes and obesity?Are diabetes, obesity, and physical inactivity happening within the same areas of the US?According to the CDC: "These data can help the public to better use existing resources for diabetes management and prevention efforts." The data comes from the Behavioral Risk Factor Surveillance System (BRFSS) through the Centers for Disease Control and Prevention (CDC), and the data vintage is 2013. To explore other county indicators, different vintages, or the original data, click here. To view the interactive map through the CDC website, click here. To learn more about the methodology of how county-level estimates are calculated, see this PDF.

West Virginia, Mississippi, and Arkansas are the U.S. states with the highest percentage of their population who are obese. The states with the lowest percentage of their population who are obese include Colorado, Hawaii, and Massachusetts. Obesity in the United States Obesity is a growing problem in many countries around the world, but the United States has the highest rate of obesity among all OECD countries. The prevalence of obesity in the United States has risen steadily over the previous two decades, with no signs of declining. Obesity in the U.S. is more common among women than men, and overweight and obesity rates are higher among African Americans than any other race or ethnicity. Causes and health impacts Obesity is most commonly the result of a combination of poor diet, overeating, physical inactivity, and a genetic susceptibility. Obesity is associated with various negative health impacts, including an increased risk of cardiovascular diseases, certain types of cancer, and diabetes type 2. As of 2022, around 8.4 percent of the U.S. population had been diagnosed with diabetes. Diabetes is currently the eighth leading cause of death in the United States.

The adult obesity rate, or the percentage of the county population (age 18 and older*) that is obese, or has a Body Mass Index (BMI) equal to or greater than 30 [kg/m2], is illustrative of a serious health problem, in Champaign County, statewide, and nationally.

The adult obesity rate data shown here spans from Reporting Years (RY) 2015 to 2024. Champaign County’s adult obesity rate fluctuated during this time, peaking in RY 2022. The adult obesity rates for Champaign County, Illinois, and the United States were all above 30% in RY 2024, but the Champaign County rate was lower than the state and national rates. All counties in Illinois had an adult obesity rate above 30% in RY 2024, but Champaign County's rate is one of the lowest among all Illinois counties.

Obesity is a health problem in and of itself, and is commonly known to exacerbate other health problems. It is included in our set of indicators because it can be easily measured and compared between Champaign County and other areas.

This data was sourced from the University of Wisconsin’s Population Health Institute’s and the Robert Wood Johnson Foundation’s County Health Rankings & Roadmaps. Each year’s County Health Rankings uses data from the most recent previous years that data is available. Therefore, the 2024 County Health Rankings (“Reporting Year” in the table) uses data from 2021 (“Data Year” in the table). The survey methodology changed in Reporting Year 2015 for Data Year 2011, which is why the historical data shown here begins at that time. No data is available for Data Year 2018. The County Health Rankings website notes to use caution if comparing RY 2024 data with prior years.

*The percentage of the county population measured for obesity was age 20 and older through Reporting Year 2021, but starting in Reporting Year 2022 the percentage of the county population measured for obesity was age 18 and older.

Source: University of Wisconsin Population Health Institute. County Health Rankings & Roadmaps 2024. www.countyhealthrankings.org.

Historical dataset showing U.S. obesity rate by year from N/A to N/A.

The prevalence of obesity in the United States has risen gradually over the past decade. As of 2023, around ** percent of the population aged 18 years and older was obese. Obesity is a growing problem in many parts of the world, but is particularly troubling in the United States. Obesity in the United States The states with the highest prevalence of obesity are West Virginia, Mississippi, and Arkansas. As of 2023, a shocking ** percent of the population in West Virginia were obese. The percentage of adults aged 65 years and older who are obese has grown in recent years, compounding health issues that develop with age. Health impacts of obesity Obesity is linked to several negative health impacts including cardiovascular disease, diabetes, and certain types of cancer. Unsurprisingly, the prevalence of diagnosed diabetes has increased in the United States over the years. As of 2022, around *** percent of the population had been diagnosed with diabetes. Some of the most common types of cancers caused by obesity include breast cancer in postmenopausal women, colon and rectum cancer, and corpus and uterus cancer.

Overview: This dataset combines publicly available data on obesity rates, poverty rates, and median household income for all 50 U.S. states from 2019 to 2023. It also includes calculated regional averages based on U.S. Census Bureau-defined regions (Northeast, Midwest, South, and West).

Use Cases - Public health research - Data visualization projects - Socioeconomic analysis - ML models exploring health + income

Sources - CDC BRFSS – Adult Obesity Prevalence Maps (2019–2023) - U.S. Census Bureau – SAIPE Datasets (2019–2023)

Tableau Dashboard View the interactive Tableau dashboard:
https://public.tableau.com/app/profile/geo.montes/viz/ObesityPovertyandIncomeintheU_S_2019-2023/Dashboard1#2

Created by Geo Montes, Informatics major at UT Austin

Historical dataset showing Latin America & Caribbean obesity rate by year from N/A to N/A.

Note: This data was created by the Center for Disease Control, not the City of Rochester. This map is zoomed in to show the CDC data at the census tract level. You can zoom out to see data for all 500 cities in the data set. This map has been built to symbolize the percentage of adults who, in 2017, had a body mass index (BMI) at/above 30.0, classifying them as obese according to self-reported data on their height on weight. However, if you click on a census tract, you can see statistics for the other public health statistics mentioned below in the "Overview of the Data" section.Overview of the Data: This service provides the 2019 release for the 500 Cities Project, based on data from 2017 or 2016 model-based small area estimates for 27 measures of chronic disease related to unhealthy behaviors (5), health outcomes (13), and use of preventive services (9). Twenty measures are based on 2017 Behavioral Risk Factor Surveillance System (BRFSS) model estimates. Seven measures (all teeth lost, dental visits, mammograms, Pap tests, colorectal cancer screening, core preventive services among older adults, and sleep less than 7 hours) kept 2016 model estimates, since those questions are only asked in even years. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. It represents a first-of-its kind effort to release information on a large scale for cities and for small areas within those cities. It includes estimates for the 500 largest US cities and approximately 28,000 census tracts within these cities. These estimates can be used to identify emerging health problems and to inform development and implementation of effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations.Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. Data sources used to generate these measures include BRFSS data (2017 or 2016), Census Bureau 2010 census population data, and American Community Survey (ACS) 2013-2017 or 2012-2016 estimates. For more information about the methodology, visit https://www.cdc.gov/500cities or contact 500Cities@cdc.gov.

Historical dataset showing Central America obesity rate by year from N/A to N/A.

Patients with obesity or overweight are at increased risk for obesity-related complications (ORCs), including cardiovascular disease. Treatment with once-weekly (OW) semaglutide 2.4 mg has demonstrated clinical efficacy, however its impact on healthcare resource utilization (HCRU) and costs warrants further investigation. This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database. Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users. HCRU and medical costs estimates at 12-month follow-up, both all-cause and ORC-related, were compared between the two cohorts. Patients treated with semaglutide 2.4 mg vs OM non-users had 37% and 21% lower incidence of all-cause inpatient (IP) and emergency room (ER) visits, respectively, and 45% and 29% lower incidence of ORC-related IP and ER visits, respectively. All-cause and ORC-related total medical costs were lower among patients treated with semaglutide 2.4 mg (11% and 15% lower, respectively), translating to an observed savings of $3,342 and $2,408 at 12 months. In patients with obesity or overweight, OW semaglutide 2.4 mg treatment was associated with decreased total medical HCRU and costs at 12 months.

Title Childhood Obese and Overweight Estimates, NM Counties 2016 - NMCHILDOBESITY2017

Summary County level childhood overweight and obese estimates for 2016 in New Mexico. Most recent data known to be available on childhood obesity

Notes This map shows NM County estimated rates of childhood overweight and obesity. US data is available upon request. Published in May, 2022. Data is most recent known sub-national obesity data set. If you know of another resource or more recent, please reach out. emcrae@chi-phi.org

Source Data set produced from the American Journal of Epidemiology and with authors and contributors out of the University of South Carolina, using data from the National Survey of Children's Health.

Journal Source Zgodic, A., Eberth, J. M., Breneman, C. B., Wende, M. E., Kaczynski, A. T., Liese, A. D., & McLain, A. C. (2021). Estimates of childhood overweight and obesity at the region, state, and county levels: A multilevel small-area estimation approach. American Journal of Epidemiology, 190(12), 2618–2629. https://doi.org/10.1093/aje/kwab176

Journal article uses data from The United States Census Bureau, Associate Director of Demographic Programs, National Survey of Children’s Health 2020 National Survey of Children's Health Frequently Asked Questions. October 2021. Available from: https://www.census.gov/programs-surveys/nsch/data/datasets.html

GIS Data Layer prepared by EMcRae_NMCDC

Feature Service https://nmcdc.maps.arcgis.com/home/item.html?id=80da398a71c14539bfb7810b5d9d5a99

Alias Definition

region Region Nationally

state State (data set is NM only but national data is available upon request)

fips_num County FIPS

county County Name

rate Rate of Obesity

lower_ci Lower Confidence Interval

upper_ci Upper Confidence Interval

fipstxt County FIPS text

Quarterly sales of weight loss and anti-obesity drug Wegovy increased more than eightfold within only one year. The drug is manufactured by Danish biopharmaceutical company Novo Nordisk, primarily known for its focus on diabetes treatments. The most recent quarterly sales figure (Q3 2025) set a record at around 20 billion Danish kroner. Why Wegovy has blockbuster potential Wegovy and Novo Nordisk have been very present in the media lately, since the drug is expected to have huge potential in markets with large populations affected by overweight and obesity. In its latest report, the World Obesity Federation estimated the global population that is obese or overweight will increase from 2.6 billion individuals in 2020 to over four billion by 2035. The United States, which is the largest pharmaceutical market globally, is also one of the most obese countries in the world. It is estimated that more than 36 percent of adult Americans are obese. Thus, the preconditions for a drug like Wegovy are more than just a given. This is also reflected in Novo Nordisk's increasing share prices and a current record-high market capitalization. The risks of weight loss drugs Wegovy seems to cut the risks of certain conditions that usually come with being overweight and obese, like stroke and heart attack. But of course, some risks must be considered. The most common side effects of the drugs are nausea, dizziness, diarrhea, and vomiting. Doctors also warn that weight loss drugs like Wegovy can lead to serious complications for patients who need anesthesia for surgery when the stomach must be empty. There is an increased risk of pulmonary aspiration since these drugs slow down digestion. Another problem weight loss drugs can cause is that people, instead of changing their lifestyle, and mostly out of convenience, immediately turn to such drugs.